

CLAIMS

What is claimed is:

1. A system for monitoring patients during a consciousness-altering therapeutic treatment session comprising:

a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session.
2. The system of claim 1, wherein said data collection module includes a patient mobile device, at least one wearable device, a sound system, and a blood pressure monitor.
3. The system of claim 2, wherein said patient mobile device is chosen from the group consisting of a smartphone and tablet, and said at least one wearable device is chosen from the group consisting of a smart watch and a fitness band.
4. The system of claim 2, wherein said data collection module includes a facilitator mobile device in electronic communication with said patient mobile device, said at least one wearable device, said sound system, and said blood pressure monitor.
5. The system of claim 4, wherein said facilitator mobile device provides audio and video feed, ePRO, eCOA, EMA, ClinRO, EHR/EMR, cognitive tasks, and therapy notes.
6. The system of claim 4, wherein said facilitator mobile device includes an application stored on non-transitory computer readable media for guiding the facilitator through the treatment session.
7. The system of claim 1, wherein said network servers include a backend with API including a relational database and external storage.

8. The system of claim 1, wherein said data collection module collects audio and music stream data with a microphone and speakers, motion and actigraphy with an accelerometer, gyroscope, and magnetometer, heart rate and blood pressure with a heart rate sensor and said blood pressure monitor, ePRO, eCOA, EMA, or ClinRO with said facilitator mobile device, and video and image stream with a camera.

9. The system of claim 1, wherein said consciousness-altering therapeutic is chosen from the group consisting of lysergic acid diethylamide (LSD), psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamine (DOB), ibogaine, ketamine, salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof.

10. The system of claim 1, wherein said system provides a feature chosen from the group consisting of automatic detection of mood swings, early onset of panic attacks, and other psychological states and behavioral correlates of consciousness altering effects of the administered therapeutic, continuous monitoring and real-time detection of adverse events related to consciousness altering treatment, automatic analysis of the clinician's/facilitator's notes and the ability to automatically identify, extract, and present critical moments, comment, and highlights of the treatment session, automatically create patient specific and/or session-specific statistics, monitoring for signs of abuse or dependence, an automatic drug provisioning system, a dosing administration tracking system, automatic detection of an inappropriate treatment setting, a digitized clinician, facilitator, and site certification system, a treatment management system, session scheduling, digital medical history, and an audit trail interface, and combinations thereof.